A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
复制标题
使用硼替佐米、聚乙二醇化脂质体阿霉素和利妥昔单抗治疗 HIV 阴性原发性渗出性淋巴瘤一例。
DOI：
--
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
R. Joyce
中科院分区：
文献类型：
--
作者：
T. Siddiqi;R. Joyce
Primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma that usually occurs in HIV-positive patients and has a very poor prognosis with limited treatment options. Prospective studies are lacking to define the standard of care for this disease, and various case series report median survival at 6 months with anthracycline-based chemotherapy. Reports of antiviral agents, immune modulators, and some targeted therapies are present in the literature with variable results. Herein, we report a case of an elderly HIV-negative man of Mediterranean origin who was diagnosed with primary effusion lymphoma and responded dramatically to 6 cycles of a combination of bortezomib, pegylated liposomal doxorubicin, and rituximab. He has since been maintained on rituximab and remains in complete remission 2 years after diagnosis. In this report, we discuss the rationale for using these agents in this patient and advocate the further study of bortezomib-based therapy in PEL.
影响因子：
20.3
作者：
Sin, Sang-Hoon;Roy, Debasmita;Dittmer, Dirk P.
通讯作者：
Dittmer, Dirk P.
影响因子：
20.3
作者：
Klass, CM;Krug, LT;Offermann, MK
通讯作者：
Offermann, MK
影响因子：
6
作者：
Matolcsy, A;Nádor, RG;Knowles, DM
通讯作者：
Knowles, DM